What is Remynd?
Remynd is a specialized clinical-stage biotechnology company dedicated to developing novel treatments for diseases rooted in cellular dysfunction, including Alzheimer's, diabetes, and epilepsy. At the core of its operations is a proprietary drug discovery platform that facilitates the identification of first-in-class small molecules and novel mechanisms-of-action. The company's most advanced asset, ReS19-T, targets the restoration of synaptic plasticity in Alzheimer's patients, while its diabetes program, ReS39, focuses on enhancing endogenous insulin production. Beyond its internal pipeline, Remynd operates a Contract Research Organization (CRO) that provides specialized CNS disorder assessment services to a global client base, further diversifying its revenue streams and scientific influence.
How much funding has Remynd raised?
Remynd has raised a total of $29.2M across 1 funding round:
Series B
$29.2M
Series B (2021): $29.2M with participation from KU Leuven, BNP Paribas Fortis, PMV Groupe, FPIM, and Korys Investments
Key Investors in Remynd
BNP Paribas Fortis
BNP Paribas Fortis, founded in 1848 and headquartered in Belgium, is a banking institution offering a variety of financial services and solutions to customers.
PMV Groupe
PMV is an investment company that focuses on the sustainable economic future of Flanders by financing promising businesses from the very first business idea to the growth and internationalization phase.
KU Leuven
KU Leuven is a leading research university in Belgium that fosters innovation through its technology transfer office, supporting the commercialization of academic research.
What's next for Remynd?
With the recent capital injection, Remynd is well-positioned to accelerate its clinical development programs and expand the reach of its proprietary drug discovery platform. The strategic focus will likely remain on advancing ReS19-T through critical clinical milestones while simultaneously exploring new therapeutic avenues for mitochondrial dysfunction in central nervous system disorders. By maintaining its dual-track approach—combining internal drug development with high-value CRO services—the company is poised to strengthen its competitive advantage. Future growth will be driven by the successful translation of its preclinical findings into viable, market-ready therapies, potentially attracting further institutional interest as the company matures toward commercialization.
See full Remynd company page
